IL18 and neoplasm: In regards to the ex vivo expansion setting, we could not distinguish any superiority in terms of anti-tumor activity in vivo among IL-7, IL-15, IL-18, IL-21 and no cytokine (NC) conditions, perhaps due to CART cell number being sufficient to eliminate tumor in all the groups.